28/01/2022 (Agence Europe) – On Friday 28 January, the European Commission granted conditional marketing authorisation to Paxlovid, an antiviral drug developed by the pharmaceutical company Pfizer. It is based on a recommendation from the EMA’s Committee for Medicinal Products for Human Use. After analysing preclinical and clinical data, the Committee judged the benefit-risk ratio of the drug to be positive. Paxlovid is recommended for adults with severe to moderate forms of Covid-19,...